GLAND PHARMA
View: Covid-19 and China are the two challenges India is struggling withIncidentally, India’s biggest pharma initial public offering capitalised on both these aspects. Last month, a Hyderabad based injectables c...
- Stock market update: 160 stocks hit 52-week highs on NSE
Overall, 31 shares were trading in green in Nifty50 index, while 19 were trading in red in the afternoon trade.
- Stock market update: Nifty Pharma index falls 1%; Biocon sheds 2%
The index was trading 0.93 per cent down at 11769.9.
- Gland Pharma stock rallies 7%, up 47 % over issue price
The stock was listed on November 20, and since then has ended lower in one session.
- Can Gland Pharma stock see more upside?
A 17%-18% jump was a good opening and the company will benefit from the fact that it has all these good long-term contracts which ensure a ...
- Stock market update: Pharma stocks fall; Sun Pharma slips 2%
The Nifty Pharma index was trading 0.77 per cent down at 11477.0.
- Gland Pharma in high demand ahead of listing
Gland Pharma shares were available at a premium of Rs 20 in the grey market during the offer subscription period between Nov 9 and 11. The ...
- Gland Pharma stock gets its mojo back as grey market premium soars again
Shares of Gland Pharma traded at a Rs 140-150 premium in the grey market, the unofficial market for trading in unlisted shares, on Tuesday....
- Why investors need to be overweight on pharma
I remain very positive on pharma. Top pick still remains Aurobindo Pharma, says Dipan Mehta.
- Sensex scales fresh record closing high, takes winning run to 8th day
Indices traded in a wide range and even plunged in the red during the day. India VIX, volatility indicator of the market, rose again, signa...
- Gland Pharma's Rs 6,480 crore IPO kicks off: Should you subscribe?
The Shanghai Fosun Pharma-owned company raised a total of Rs 1,943.86 crore from 70 anchor investors.
- Gland has a robust business, and some risks you need to factor in
ALL POSITIVES fully priced in, which leaves little on the table; Chinese ownership comes with growth opportunities and potential shocks
- What’s driving PE firms to pay "strategic" premium for Indian pharma?
Data from the recent deal flows also suggest that many of these financial investors are also willing to pay more than strategics. Historica...
- Zydus Cadila in talks to sell two units for Rs 1,200 crore
This is part of a broader strategy to reduce debt in the company’s capital structure after it borrowed more to help finance the Rs 4,600-cr...
- GAVIS Pharma LLC looking to exit Bengaluru-based Wintac Ltd
Gavis Pharma LLC is now exploring options to exit its listed Indian arm. Wintac Ltd was not part of the 2015 deal struck between Lupin & Ga...
- Gland Pharma promoters put their 60 per cent stake on the block
Promoters of Hyderabad-based speciality injectable drugs maker Gland Pharma have decided to put their controlling stake on the block.
- How will Indian pharma sector shape up under new government?
Several global companies have aggressively joined hands with Indian companies due to India’s strong generic pharma position.
- India Inc flaunts the colour blue
Over half of the Sensex companies predominantly use blue as their corporate colours, a SundayET study revealed.
MORE NEWS
